Graft Versus Host Disease (GVHD) – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Graft Versus Host Disease (GVHD) – Pipeline Review, H2 2019’, provides an overview of the Graft Versus Host Disease (GVHD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (GVHD)

– The report reviews pipeline therapeutics for Graft Versus Host Disease (GVHD) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Graft Versus Host Disease (GVHD) therapeutics and enlists all their major and minor projects

– The report assesses Graft Versus Host Disease (GVHD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (GVHD)”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Graft Versus Host Disease (GVHD)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“AbbVie Inc

AbGenomics International Inc

Adienne Pharma & Biotech

Alpine Immune Sciences Inc

Amgen Inc

AnaptysBio Inc

apceth Biopharma GmbH

ASC Therapeutics Inc

AstraZeneca Plc

Athersys Inc

Bellicum Pharmaceuticals Inc

Biocon Ltd

Biogen Inc

BioIncept LLC

BlueRock Therapeutics

Boryung ViGenCell Inc

Bristol-Myers Squibb Co

Capricor Therapeutics Inc

Celgene Corp

Cellect Biotechnology Ltd

Cellective BioTherapy Inc

Cellix Bio Pvt Ltd

CheckPoint Immunology Inc

Clinigen Group Plc

CSL Ltd

CTI BioPharma Corp

Cytodyn Inc

Cytopeutics Pte Ltd

Daewoong Pharmaceutical Co Ltd

Dualogics Corp

Eli Lilly and Co

Elsalys Biotech SA

enGene Inc

Enlivex Therapeutics Ltd

ExCellThera Inc

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

Fujifilm Holdings Corp

Generon (Shanghai) Corp Ltd

GlaxoSmithKline Plc

Glia LLC

Humanigen Inc

Immplacate

Immune Modulation Inc

ImmuneTarget Inc

Imstem Biotechnology Inc

Incyte Corp

Inspyr Therapeutics Inc

Jazz Pharmaceuticals Plc

JN Biosciences LLC

Kadmon Corp LLC

Kalytera Therapeutics Inc

Kamada Ltd

Kiadis Pharma NV

Kiniksa Pharmaceuticals Corp

Kymab Ltd

LG Chem Ltd

MaaT Pharma

Machavert Pharmaceuticals LLC

Magenta Therapeutics Inc

Mallinckrodt Plc

Medac Pharma Inc

Medicenna Therapeutics Corp

Medsenic SAS

Mesoblast Ltd

Millennium Pharmaceuticals Inc

NapaJen Pharma Inc

Neovii Pharmaceuticals AG

Novartis AG

Ocugen Inc

OncoImmune Inc

OSE Immunotherapeutics

Panorama Research Inc

Pfizer Inc

Pharmicell Co Ltd

Pluristem Therapeutics Inc

Precision Biosciences Inc

REGiMMUNE Corp

Sanofi

SCM lifescience Co Ltd

Seattle Genetics Inc

Secura Bio Inc

Seres Therapeutics Inc

STERO Biotechs Ltd

Suzhou Connect Biopharmaceuticals Ltd

Syndax Pharmaceuticals Inc

Synthetic Biologics Inc

Taiwan Bio Therapeutics Co Ltd

Takeda Pharmaceutical Co Ltd

Targazyme Inc

TCF GmbH

TeraImmune Inc

TGV Laboratories Inc

United BioPharma Inc

Vault Pharma Inc

VBI Vaccines Inc

Visterra Inc

Xenikos BV

Xenothera SAS

XL-protein GmbH”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Graft Versus Host Disease (GVHD) Overview 7

Graft Versus Host Disease (GVHD) Therapeutics Development 8

Graft Versus Host Disease (GVHD) Therapeutics Assessment 25

Graft Versus Host Disease (GVHD) Companies Involved in Therapeutics Development 37

Graft Versus Host Disease (GVHD) Drug Profiles 66

Graft Versus Host Disease (GVHD) Dormant Projects 466

Graft Versus Host Disease (GVHD) Discontinued Products 471

Graft Versus Host Disease (GVHD) Product Development Milestones 472

Appendix 485

List of Tables

“List of Tables

Table 1: Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2019

Table 2: Number of Products under Development by Companies, H2 2019

Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Table 6: Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Table 7: Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Table 8: Number of Products under Development by Universities/Institutes, H2 2019

Table 9: Products under Development by Companies, H2 2019

Table 10: Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 11: Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 12: Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Table 13: Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Table 14: Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Table 15: Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Table 16: Products under Development by Companies, H2 2019 (Contd..7), H2 2019

Table 17: Products under Development by Universities/Institutes, H2 2019

Table 18: Number of Products by Stage and Target, H2 2019

Table 19: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Table 20: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019

Table 21: Number of Products by Stage and Mechanism of Action, H2 2019

Table 22: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Table 23: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019

Table 24: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019

Table 25: Number of Products by Stage and Route of Administration, H2 2019

Table 26: Number of Products by Stage and Molecule Type, H2 2019

Table 27: Graft Versus Host Disease (GVHD) – Pipeline by AbbVie Inc, H2 2019

Table 28: Graft Versus Host Disease (GVHD) – Pipeline by AbGenomics International Inc, H2 2019

Table 29: Graft Versus Host Disease (GVHD) – Pipeline by Adienne Pharma & Biotech, H2 2019

Table 30: Graft Versus Host Disease (GVHD) – Pipeline by Alpine Immune Sciences Inc, H2 2019

Table 31: Graft Versus Host Disease (GVHD) – Pipeline by Amgen Inc, H2 2019

Table 32: Graft Versus Host Disease (GVHD) – Pipeline by AnaptysBio Inc, H2 2019

Table 33: Graft Versus Host Disease (GVHD) – Pipeline by apceth Biopharma GmbH, H2 2019

Table 34: Graft Versus Host Disease (GVHD) – Pipeline by ASC Therapeutics Inc, H2 2019

Table 35: Graft Versus Host Disease (GVHD) – Pipeline by AstraZeneca Plc, H2 2019

Table 36: Graft Versus Host Disease (GVHD) – Pipeline by Athersys Inc, H2 2019

Table 37: Graft Versus Host Disease (GVHD) – Pipeline by Bellicum Pharmaceuticals Inc, H2 2019

Table 38: Graft Versus Host Disease (GVHD) – Pipeline by Biocon Ltd, H2 2019

Table 39: Graft Versus Host Disease (GVHD) – Pipeline by Biogen Inc, H2 2019

Table 40: Graft Versus Host Disease (GVHD) – Pipeline by BioIncept LLC, H2 2019

Table 41: Graft Versus Host Disease (GVHD) – Pipeline by BlueRock Therapeutics, H2 2019

Table 42: Graft Versus Host Disease (GVHD) – Pipeline by Boryung ViGenCell Inc, H2 2019

Table 43: Graft Versus Host Disease (GVHD) – Pipeline by Bristol-Myers Squibb Co, H2 2019

Table 44: Graft Versus Host Disease (GVHD) – Pipeline by Capricor Therapeutics Inc, H2 2019

Table 45: Graft Versus Host Disease (GVHD) – Pipeline by Celgene Corp, H2 2019

Table 46: Graft Versus Host Disease (GVHD) – Pipeline by Cellect Biotechnology Ltd, H2 2019

Table 47: Graft Versus Host Disease (GVHD) – Pipeline by Cellective BioTherapy Inc, H2 2019

Table 48: Graft Versus Host Disease (GVHD) – Pipeline by Cellix Bio Pvt Ltd, H2 2019

Table 49: Graft Versus Host Disease (GVHD) – Pipeline by CheckPoint Immunology Inc, H2 2019

Table 50: Graft Versus Host Disease (GVHD) – Pipeline by Clinigen Group Plc, H2 2019

Table 51: Graft Versus Host Disease (GVHD) – Pipeline by CSL Ltd, H2 2019

Table 52: Graft Versus Host Disease (GVHD) – Pipeline by CTI BioPharma Corp, H2 2019

Table 53: Graft Versus Host Disease (GVHD) – Pipeline by Cytodyn Inc, H2 2019

Table 54: Graft Versus Host Disease (GVHD) – Pipeline by Cytopeutics Pte Ltd, H2 2019

Table 55: Graft Versus Host Disease (GVHD) – Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2019

Table 56: Graft Versus Host Disease (GVHD) – Pipeline by Dualogics Corp, H2 2019

Table 57: Graft Versus Host Disease (GVHD) – Pipeline by Eli Lilly and Co, H2 2019

Table 58: Graft Versus Host Disease (GVHD) – Pipeline by Elsalys Biotech SA, H2 2019

Table 59: Graft Versus Host Disease (GVHD) – Pipeline by enGene Inc, H2 2019

Table 60: Graft Versus Host Disease (GVHD) – Pipeline by Enlivex Therapeutics Ltd, H2 2019”

List of Figures

“List of Figures

Figure 1: Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2019

Figure 2: Number of Products under Development by Companies, H2 2019

Figure 3: Number of Products under Development by Universities/Institutes, H2 2019

Figure 4: Number of Products by Top 10 Targets, H2 2019

Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019

Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019

Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Figure 10: Number of Products by Top 10 Molecule Types, H2 2019

Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports